U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H15ClNO4.Na.3H2O
Molecular Weight 433.815
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INDOMETHACIN SODIUM

SMILES

O.O.O.[Na+].COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC([O-])=O

InChI

InChIKey=UHYAQBLOGVNWNT-UHFFFAOYSA-M
InChI=1S/C19H16ClNO4.Na.3H2O/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12;;;;/h3-9H,10H2,1-2H3,(H,22,23);;3*1H2/q;+1;;;/p-1

HIDE SMILES / InChI

Molecular Formula C19H16ClNO4
Molecular Weight 357.788
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363

Indometacin (INN and BAN) or indomethacin (AAN, USAN, and former BAN) is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Indometacin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Indometacin is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease, Moderate to severe ankylosing spondylitis, Moderate to severe osteoarthritis, Acute painful shoulder (bursitis and/or tendinitis), Acute gouty arthritis. In general, adverse effects seen with indomethacin are similar to all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, it inhibits the production of prostaglandins in the stomach and intestines, which maintain the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indomethacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indomethacin.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
INDOCIN

Approved Use

TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1).

Launch Date

1965
Primary
INDOCIN

Approved Use

TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1).

Launch Date

1965
Primary
INDOCIN

Approved Use

TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1).

Launch Date

1965
Primary
INDOCIN

Approved Use

TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1).

Launch Date

1965
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
2369 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7762 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.22 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Stimulation of cyclooxygenase-2-activity by nitric oxide-derived species in rat chondrocyte: lack of contribution to loss of cartilage anabolism.
2001-04-15
Inactivation of creatine kinase during the interaction of indomethacin with horseradish peroxidase and hydrogen peroxide: involvement of indomethacin radicals.
2001-03-14
Indomethacin prevents the induction of inducible nitric oxide synthase in murine peritoneal macrophages and decreases their nitric oxide production.
2001-03-09
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
2001-03-09
Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo.
2001-03-01
Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells.
2001-03
Effect of indomethacin on gallbladder inflammation and contractility during acute cholecystitis.
2001-03
Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery.
2001-03
Increased 15-HPETE production decreases prostacyclin synthase activity during oxidant stress in aortic endothelial cells.
2001-02-01
Indomethacin increases 15-PGDH mRNA expression in HL60 cells differentiated by PMA.
2001-02
Does exposure to magnesium sulfate in utero decrease the risk of necrotizing enterocolitis in premature infants?
2001-02
Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor.
2001-02
Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats.
2001-02
Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats.
2001-01-05
An investigation into the thermal behaviour of an amorphous drug using low frequency dielectric spectroscopy and modulated temperature differential scanning calorimetry.
2001-01
Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans.
2001-01
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
2001-01
Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells.
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen.
2000-12-08
Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model.
2000-12
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells.
2000-11-17
Role of BAX in the apoptotic response to anticancer agents.
2000-11-03
Role of endothelin-converting enzyme-1 in the suppression of constitutive nitric oxide synthase in rat gastric mucosal injury by indomethacin.
2000-11
Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril.
2000-11
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin.
2000-11
Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats.
2000-11
Indomethacin inhibits the accumulation of tumor cells in mouse lungs and subsequent growth of lung metastases.
2000-10-29
A case of living-related kidney transplantation in Bartter's syndrome.
2000-10
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression.
2000-09-27
Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways.
2000-09-08
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.
2000-09-07
Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS-deficient mice.
2000-09-01
Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells.
2000-09
Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action?
2000-08
Chronic intrathecal cannulation enhances nociceptive responses in rats.
2000-08
Ibuprofen as effective as indomethacin for patent ductus arteriosus.
2000-07-25
Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells.
2000-07
Indomethacin decreases insulin secretion in patients with type 2 diabetes mellitus.
2000-07
Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate.
2000-06-15
The influence of indomethacin on the acth secretion induced by central stimulation of adrenergic receptors.
2000-06
Effects of hydrogen peroxide scavenger Catalase on villous microcirculation in the rat small intestine in a model of inflammatory bowel disease.
2000-05
The role of nitric oxide and prostaglandin E2 on the hyperalgesia induced by excitatory amino acids in rats.
2000-04
Persistent pulmonary hypertension after maternal naproxen ingestion in a term newborn: a case report.
2000
[Effect of carrageenan and indomethacin on the growth of a murine fibrosarcoma].
2000
Matrix metalloproteinases 2 and 9 in indomethacin-induced rat gastric ulcer.
2000
Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem.
1979-09-15
[Intrahepatic cholestasis following treatment with penicillamine D and indomethacine].
1976-05-28
Letter: Aspirin sensitivity: other drugs.
1975-02
[Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis].
1975-02
Patents

Sample Use Guides

INDOCIN 75-150 mg daily in 3 or 4 divided doses.
Route of Administration: Oral
U251 cells were incubated for 24 h with different concentrations of indomethacin (0.03, 0.06, 0.13, 0.25, 0.5, 1 mkM), diclofenac (DIC),naproxen (NAP), or ketoprofen (KET), and the cell viability was assessed by MTT or crystal violet (CV) tests.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:56:52 GMT 2025
Edited
by admin
on Mon Mar 31 17:56:52 GMT 2025
Record UNII
0IMX38M2GG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INDOMETHACIN SODIUM SALT TRIHYDRATE
MI  
Preferred Name English
INDOMETHACIN SODIUM
ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
INDOMETHACIN SODIUM TRIHYDRATE
Common Name English
INDOMETACIN SODIUM HYDRATE [JAN]
Common Name English
INDOMETHACIN SODIUM [USAN]
Common Name English
SODIUM INDOMETHACIN TRIHYDRATE
Common Name English
INDOMETHACIN SODIUM [ORANGE BOOK]
Common Name English
INDOMETHACIN SODIUM [VANDF]
Common Name English
SODIUM 1-(P-CHLOROBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETATE, TRIHYDRATE
Systematic Name English
1H-INDOLE-3-ACETIC ACID, 1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-, SODIUM SALT, TRIHYDRATE
Common Name English
Indometacin sodium [WHO-DD]
Common Name English
Indometacin sodium trihydrate [WHO-DD]
Common Name English
INDOMETACIN SODIUM TRIHYDRATE
Common Name English
INDOMETACIN SODIUM [JAN]
Common Name English
INDOMETACIN SODIUM HYDRATE
Common Name English
INDOMETHACIN SODIUM SALT TRIHYDRATE [MI]
Common Name English
INDOMETACIN SODIUM [MART.]
Common Name English
INDOMETHACIN SODIUM [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1323
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
Code System Code Type Description
MERCK INDEX
m6279
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY Merck Index
SMS_ID
100000086425
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
ChEMBL
CHEMBL6
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
RXCUI
258329
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
EPA CompTox
DTXSID00225256
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
DRUG BANK
DBSALT001435
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
CAS
74252-25-8
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
WIKIPEDIA
Indomethacin sodium
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
DAILYMED
0IMX38M2GG
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
RXCUI
1294612
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
ALTERNATIVE
USAN
X-78
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
PUBCHEM
23674731
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
FDA UNII
0IMX38M2GG
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
NCI_THESAURUS
C47999
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
EVMPD
SUB02677MIG
Created by admin on Mon Mar 31 17:56:52 GMT 2025 , Edited by admin on Mon Mar 31 17:56:52 GMT 2025
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
The sum of the percentages of indomethacin related compound A and indomethacin related compound B is NMT 0.2%.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
The sum of the percentages of indomethacin related compound A and indomethacin related compound B is NMT 0.2%.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY